Table 2.

Subgroup analyses of SII for prognosis in patients with RCC.

Subgroups	No. of studies	No. of patients	Effects model	HR (95%CI)	p	Heterogeneity I 2(%) Ph
OS
Total	10	3,180	Random	1.75 (1.33-2.30)	<0.001	92.4	<0.001
Region
Asia	6	1,417	Random	1.62 (1.12-2.34)	0.010	85.4	<0.001
Non-Asia	4	1,763	Random	1.92 (1.33-2.78)	0.001	88	<0.001
Cancer type
Localized RCC	2	822	Fixed	1.96 (1.41-2.71)	<0.001	0	0.363
mRCC	8	2,358	Random	1.70 (1.26-2.30)	0.001	93.2	<0.001
Cut-off value
≤730	6	2,462	Random	1.81 (1.41-2.30)	<0.001	72.5	0.003
>730	4	718	Random	1.64 (0.92-2.93)	0.096	92.2	<0.001
Treatments
Surgery	4	1,466	Random	1.37 (1.03-1.81)	0.029	85.5	<0.001
TKIs	4	1,214	Fixed	1.87 (1.58-2.20)	<0.001	27.8	0.245
Surgery + TKIs	1	187	–	2.08 (1.40-3.09)	<0.001	–	–
ICIs	1	313	–	2.99 (2.07-4.31)	<0.001	–	–
Sample size
≤200	5	771	Random	1.51 (1.04-2.18)	0.029	82.2	<0.001
>200	5	2,409	Random	1.97 (1.42-2.73)	<0.001	85.0	<0.001
PFS/DFS
Total	4	740	Random	1.22 (0.84-1.76)	0.293	85.9	<0.001
Region
Asia	3	405	Fixed	1.02 (1.00-1.04)	0.048	0	0.943
Non-Asia	1	335	–	1.84 (1.43-2.36)	<0.001	–	–
Cancer type
Localized RCC	1	176	–	1.14 (0.53-2.43)	0.738	–	–
mRCC	3	564	Random	1.23 (0.81-1.88)	0.330	90.6	<0.001
Cut-off value
≤730	1	335	–	1.84 (1.43-2.36)	<0.001	–	–
>730	3	405	Fixed	1.02 (1.00-1.04)	0.048	0	0.943
Treatments
Surgery	2	207	Fixed	1.02 (1.00-1.04)	0.047	0	0.777
TKIs	2	533	Random	1.38 (0.74-2.55)	0.311	83.6	0.014
Sample size
≤200	3	405	Fixed	1.02 (1.00-1.04)	0.048	0	0.943
>200	1	335	-0	1.84 (1.43-2.36)	<0.001	–	–
CSS
Total	2	1,259	Random	1.46 (0.68-3.12)	0.332	81.5	0.020

RCC, renal cell carcinoma; mRCC, metastatic renal cell carcinoma; TKIs, tyrosine kinase inhibitors; OS, overall survival; PFS, progression-free survival; DFS, disease-free survival; CSS, cancer-specific survival; ICIs, immune checkpoint inhibitors.